

## Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022

July 27, 2022

## **Conference Call and Webcast to Follow**

WASHINGTON, July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, August 3, 2022, during which management will discuss the second quarter 2022 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 4304469.

The conference call will be broadcast simultaneously and archived on Vanda's website, <u>www.vandapharma.com</u>. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, August 3, 2022, beginning at 8:30 PM ET and will be accessible until Wednesday, August 10, 2022, at 8:30 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 4304469.

## About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit <u>www.vandapharma.com</u> and follow us on Twitter @vandapharma.

## Corporate Contact:

Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 pr@vandapharma.com

Elizabeth Van Every Head of Corporate Affairs Vanda Pharmaceuticals Inc. 202-734-3400 pr@vandapharma.com

<sup>C</sup> View original content: <u>https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-second-quarter-2022-financial-results-on-august-3-2022-301594781.html</u>

SOURCE Vanda Pharmaceuticals Inc.